Tumor-invading protein delivers therapy straight to the brain, study finds

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A protein designed by Cedars-Sinai Cancer investigators can cross the protective blood-brain barrier safely and deliver therapy directly into cancerous tumor cells, a preclinical study shows. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

KRAS is the most frequently mutated oncogene across all human cancers. Although different KRAS mutations have long been thought to exert the same cancer-driving effects, a new study led by UT Southwestern Medical Center researchers suggests that different KRAS mutation types can variously impact how cancer cells interact with immune cells, significantly affecting the malignant cells’ behavior. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login